

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



1900 00003

1998

ADVICE

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) 9706378

(51) International Patent Classification 6 : A61K 39/00, 45/00, 45/05, 38/00, 38/16, 38/18, G01N 33/53, 33/536, 33/543, 33/564, 33/566, C12N 5/00, 5/06, C07K 14/00, 14/435, 14 /47, 14 /475		A1	(11) International Publication Number: WO 96/19236 (43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/US95/16596 (22) International Filing Date: 20 December 1995 (20.12.95) (30) Priority Data: 112094 21 December 1994 (21.12.94) IL 114460 5 July 1995 (05.07.95) IL (71) Applicant (for all designated States except US): YEDA RE- SEARCH AND DEVELOPMENT CO. LTD. (IL/IL); Weiz- mann Institute of Science, P.O. Box 95, 76100 Rehovot (IL). (72) Inventors; and (75) Inventors/Applicants (for US only): COHEN, Irun, R. [US/IL]; 11 Hankin Street, 76354 Rehovot (IL). ELIAS, Dana [IL/IL]; 57 Derech Yavne, 76344 Rehovot (IL). FRIDKIN, Matityahu [IL/IL]; 23 Miller Street, 76284 Rehovot (IL). (74) Agent: BROWDY, Roger, L.; Browdy and Neimark, Suite 300, 419 Seventh Street N.W., Washington, DC 20004 (US).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: PEPTIDE p277 ANALOGS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES (57) Abstract A peptide having the structure of the p277 sequence of hsp60 in which one or both cysteine residues are replaced by valine residues and/or in which the Thr ¹⁹ residue is replaced by Lys, has substantially the same biological activity as p277 but with substantially improved stability. The novel p277 analogues may be used for every purpose that p277 can be used.			

9706378-8